Newron and Myung In Pharm License Agreement for Evenamide in South Korea

Newron Pharmaceuticals S.p.A. and Myung In Pharm Co. Ltd. have announced a licensing agreement focused on evenamide in South Korea. Myung In Pharm will develop, manufacture, and commercialize this add-on therapy for treatment-resistant schizophrenia. The company will also contribute 10% of the patients for Newron's Phase III trial while sharing in global development costs.

Newron will receive payments based on development milestones and net sales royalties. The pivotal Phase III trial, scheduled for the first half of 2025, will involve at least 600 patients and will be led by Newron. Myung In Pharm will manage patient enrollment and data collection in South Korea.

This collaboration allows both companies to leverage their expertise in CNS therapies to address the unmet medical need for a glutamatergic mechanism of action in schizophrenia treatment in South Korea.